In the case of prostate cancer, it will be interesting to simultaneously analyze other markers of prostate cancer progression, e.g., TMPRSS-ERG fusion events [36], to see if their presence also correlates with upregulation of Lipocalin 2. The gene discussed is LCN2; the disease is prostate carcinoma.